Recombinant activated factor VII (Novo7®) in patients with ventricular assist devices: Case report and review of the current literature

Journal of Cardiothoracic Surgery

Volumn 2, Issue 1, 2007, Pages

  Heise, Daniel ^a   Bräuer, Anselm ^a   Quintel, Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; BLEEDING; CASE REPORT; FATALITY; HEART ASSIST DEVICE; HEART SURGERY; HUMAN; MALE; METHODOLOGY; RESUSCITATION; REVIEW;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY RESUSCITATION; FACTOR VIIA; FATAL OUTCOME; HEART-ASSIST DEVICES; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 37749051439     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-2-47     Document Type: Review

References (24)

1. Williams M Casher J Joshi N Hankinson T Warren M Oz M Naka Y Mancini D: Insertion of a left ventricular assist device in patients without thorough transplant evaluations: A worthwhile risk? J Thorac Cardiovasc Surg 2003, 126(2):436-441. 10.1016/S0022-5223(03)00056-4 12928641
2. Goldstein DJ Beauford RB: Left ventricular assist devices and bleeding: adding insult to injury. Ann Thorac Surg 2003, 75(6 Suppl):S42-7. 10.1016/S0003-4975(03)00478-8 12820734
3. Mahdy AM Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth 2004, 93(6):842-858. 10.1093/bja/aeh227 15277296
4. Flynn JD Camp PC Jr. Jahania MS Ramaiah C Akers WS: Successful treatment of refractory bleeding after bridging from acute to chronic left ventricular assist device support with recombinant activated factor VII. Asaio J 2004, 50(5):519-521. 10.1097/01.MAT.0000136516.16726.35 15497395
5. Kogan A Berman M Kassif Y Raanani E Stamler A Ben Gal T Stein M Erez E Vidne BA Sahar G: Use of recombinant factor VII to control bleeding in a patient supported by right ventricular assist device after heart transplantation. J Heart Lung Transplant 2005, 24(3):347-349. 10.1016/ j.healun.2003.12.001 15737765
6. Potapov EV Pasic M Bauer M Hetzer R: Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002, 74(6):2182-2183. 10.1016/ S0003-4975(02)04105-X 12643420
7. Zietkiewicz M Garlicki M Domagala J Wierzbicki K Drwila R Pfitzner R Dziatkowiak A: Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002, 123(2):384-385. 10.1067/ mtc.2002.119328 11828314
8. Koch CG Li L Duncan AI Mihaljevic T Cosgrove DM Loop FD Starr NJ Blackstone EH: Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006, 34(6):1608-1616. 10.1097/ 01.CCM.0000217920.48559.D8 16607235
9. Mauermann WJ Nemergut EC: The anesthesiologist's role in the prevention of surgical site infections. Anesthesiology 2006, 105(2):413-21; quiz 439-40 10.1097/00000542-200608000-00025 16871076
10. Taylor RW O'Brien J Trottier SJ Manganaro L Cytron M Lesko MF Arnzen K Cappadoro C Fu M Plisco MS Sadaka FG Veremakis C: Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006, 34(9):2302-8; quiz 2309 10.1097/ 01.CCM.0000234034.51040.7F 16849995
11. Vamvakas EC Carven JH: Allogeneic blood transfusion and postoperative duration of mechanical ventilation: Effects of red cell supernatant, platelet supernatant, plasma components and total transfused fluid. Vox Sang 2002, 82(3):141-149. 10.1046/j.1423-0410.2002.00155.x 11952989
12. Nuttall GA Oliver WC Jr. Santrach PJ McBane RD Erpelding DB Marver CL Zehr KJ: Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: A prospective observational case series. Anesth Analg 2003, 96(2):344-50, table of contents. 10.1097/ 00000539-200302000-00009 12538175
13. Levy MM Fink MP Marshall JC Abraham E Angus D Cook D Cohen J Opal SM Vincent JL Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31(4):1250-1256. 10.1097/ 01.CCM.0000050454.01978.3B 12682500
14. Kaplan M Cimen S Kut MS Demirtas MM: Cardiac operations for patients with chronic liver disease. Heart Surg Forum 2002, 5(1):60-65. 11937465
15. Yende S Wunderink RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001, 29(12):2271-2275. 10.1097/ 00003246-200112000-00006 11801823
16. Parr KG Patel MA Dekker R Levin R Glynn R Avorn J Morse DS: Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth 2003, 17(2):176-181. 10.1053/jcan.2003.44 12698398
17. Liu B Belboul A Larsson S Roberts D: Factors influencing haemostasis and blood transfusion in cardiac surgery. Perfusion 1996, 11(2):131-143. 8740354
18. Martinowitz U Michaelson M: Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005, 3(4):640-648. 10.1111/j.1538-7836.2005.01203.x 15842347
19. Oh JJ Akers WS Lewis D Ramaiah C Flynn JD: Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 2006, 26(4):569-577. 10.1592/phco.26.4.576 16553518
20. Levi M Peters M Buller HR: Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005, 33(4):883-890. 10.1097/01.CCM.0000159087.85970.38 15818119
21. Marson F Farnia A Callegher L Casagrande L Surdu M Sarpellon M: Use of recombinant activated factor VII (rFVIIa-NovoSeven) in the treatment of uncontrolled postsurgical hemorrhage in a patient with deep venous thrombosis and caval filter. A case report. Minerva Anestesiol 2006, 72(7-8):675-682. 16865086
22. O'Connell KA Wood JJ Wise RP Lozier JN Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. Jama 2006, 295(3):293-298. 10.1001/jama.295.3.293 16418464
23. Loudon B Smith MP: Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: A pharmacoeconomic evaluation. Intern Med J 2005, 35(8):463-467. 10.1111/ j.1445-5994.2005.00878.x 16176468
24. Clark AD Gordon WC Walker ID Tait RC: 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004, 86(2):120-124. 10.1111/j.0042-9007.2004.00393.x 15023181